Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

Siriraj Hospital

Status: Completed

Conditions: Glaucoma Secondary to Eye Inflammation; Intraocular Pressure; Neovascular Glaucoma; Vascular Endothelial Growth Factor Overexpression

Treatments: Drug: Aflibercept Ophthalmic

Study type: Interventional

Funder types: Other

Identifiers

NCT04970251

Si726/2018

Details and patient eligibility

About

Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG).

Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Consecutive patients with neovascular glaucoma who presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand during November 2018 to October 2019.
• Aged more than 18 year-old

Exclusion criteria

• Patients who received any anti-vascular endothelial growth factor treatment before participation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)